Vitroscope raises $5M seed to turn living human tissue into drug discovery data
What's the deal? Norwegian biotech VitroscopeDealroom has a profile for this one. Try Dealroom → has raised a $5 million seed round, part of $7 million in total new funding, to scale perfusion platforms that keep living human tissue viable for days. Cerberus VenturesDealroom has a profile for this one. Try Dealroom → and YZR CapitalDealroom has a profile for this one. Try Dealroom → co-led the round, with Arcas Ventures, Golden Egg CheckDealroom has a profile for this one. Try Dealroom →, Devico Invest, and angel investors Carles ReinaDealroom has a profile for this one. Try Dealroom →, Fàtima Godall, and Oskari PétasDealroom has a profile for this one. Try Dealroom → participating. The Research Council of NorwayDealroom has a profile for this one. Try Dealroom → added $2 million in non-dilutive funding.
What's the endgame? Vitroscope wants to replace static well plates, which cannot replicate the flow and oxygen conditions that advanced tissue models need. Its benchtop vitro.alive system runs six parallel experiments with programmable flow and real-time control of oxygen, pH, and temperature. In one trial, the company and Instant BioDealroom has a profile for this one. Try Dealroom → kept vascularised human brain organoids alive under perfusion for seven days.
What's the money for? The funding will support the commercial rollout of vitro.alive and validation of vitro.scale, a higher-throughput platform built for 96 parallel experiments. Customer testing of vitro.scale is expected to begin in 2027, ahead of a planned 2028 launch. Vitroscope has raised $8.8 million to date.
Why it matters: "Drug discovery and development need data that allows researchers to actually predict how patients will respond, and Vitroscope generates it at the source," said Markus Feuerecker, founding and managing partner at YZR Capital. The pitch is to feed richer, longitudinal data into pharmaceutical research long before the first clinical trial.
Why now? Regulators are opening the door to human-relevant alternatives, with US Food and Drug Administration guidance outlining how developers can validate new approach methodologies such as organoids and organ-on-chip systems. Strategic interest is building too: Bruker announced a majority investment in organ-on-chip company MIMETAS in August 2026.
The signal: At $5 million, Vitroscope's seed sits in the 95th percentile of all-time deep tech seed rounds in Norway, a sign of growing conviction in living-tissue platforms. But the financing is a bet on a maturing field, not yet proof that such systems can reliably replace established preclinical tests at scale.
Read more: Tech.eu
Image credit: Vitroscope
